Does Acute Pyelonephritis Skew Outcomes in Registrational Trials of Novel Antibiotics for Complicated Urinary Tract Infections? A Systematic Review and Meta-analysis
Open Access
- 27 August 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Abstract
Background: Acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) are pooled in randomized controlled trials (RCTs) of antibiotics. We assessed whether outcomes differ between subtypes and which component of the composite endpoint drives any difference. Methods: Across 10 registrational RCTs, we estimated the AP-versus-cUTI treatment effect on the composite primary endpoint (clinical cure plus microbiologic eradication at test of cure [TOC]) using random-effects risk ratios, risk difference, odds ratio, and leave-one-out sensitivity analyses. Between-arm differences in the composite and components were correlated across trials; operative definitions and stratified-reporting practices were extracted. Results: From 5971 patients (3393 AP; 2578 other cUTI), AP showed higher cure at TOC (pooled risk ratio = 1.12; 95% CI 1.03–1.23; I2 = 82%; 95% prediction interval 0.86–1.46). Between-arm differences in the composite correlated strongly with those in microbiologic eradication (r = 0.98) but weakly with those in clinical cure (r = 0.30). In the single trial with subtype-stratified components (ADAPT-PO), the AP-versus-cUTI gap was larger in microbiologic eradication (+15.6 percentage point [pp]) than in clinical response (+3.5 pp); whether this generalizes to the remaining 9 trials could not be tested. Risk of bias was overall some concerns in 9/10 trials, mostly for missing outcome data and selection of the reported result. Conclusions: Acute pyelonephritis achieved higher cure rates at TOC than other cUTIs. Heterogeneity in operative AP/cUTI definitions and limited stratified reporting of component outcomes reduce interstudy comparability. Trials should harmonize definitions, prespecify stratification by subtype, and disclose clinical and microbiologic outcomes separately.Keywords
This publication has 20 references indexed in Scilit:
- Establishing core competencies for antimicrobial stewardship teams: a consensus development using the modified Delphi technique—an European Society of Clinical Microbiology and Infectious Diseases Study Group for Antimicrobial Stewardship position paperClinical Microbiology and Infection, 2025
- Short vs. long antibiotic treatment for pyelonephritis and complicated urinary tract infections: a living systematic review and meta-analysis of randomized controlled trialsClinical Microbiology and Infection, 2025
- Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and AdultsJAMA Network Open, 2024
- European Association of Urology Guidelines on Urological Infections: Summary of the 2024 GuidelinesEuropean Urology, 2024
- Antibiotic management of urinary tract infections in the post-antibiotic era: a narrative review highlighting diagnostic and antimicrobial stewardshipClinical Microbiology and Infection, 2022
- Assessing risk of bias in a randomized trial2019
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract InfectionJAMA, 2018
- Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines PanelEuropean Urology, 2017
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)The Lancet, 2015
- The clinical spectrum of acute ‘uncomplicated’ pyelonephritis from an emergency medicine perspectiveInternational Journal of Antimicrobial Agents, 2008